Showing 51-60 of 9661 results for "".
- Phase 3 Icotrokinra Data Show Joint and Skin Improvements in Psoriatic Arthritishttps://practicaldermatology.com/news/phase-3-icotrokinra-data-show-joint-and-skin-improvements-in-psoriatic-arthritis/2488969/Once-daily oral icotrokinra (ICOTYDE; Johnson & Johnson) significantly improved joint disease activity compared with placebo in biologic-naive adults with active psoriatic arthritis (PsA), according to Phase 3 ICONIC-PsA 1 results presented at the American College of Rh
- BE BOLD: Bimekizumab Maintains Higher ACR50 Responses vs Risankizumab at Week 24https://practicaldermatology.com/news/bimekizumab-maintains-higher-acr50-responses-vs-risankizumab-at-week-24/2488973/New Phase 3b BE BOLD trial results showed that bimekizumab-bkzx (Bimzelx; UCB) maintained numerically higher joint response rates than risankizumab-rzaa (Skyrizi; AbbVie) through 24 weeks in adults with active psoriatic arthritis (PsA), following statistically significant superiority at Week 16.<
- Review: Targeted Therapies Transform Psoriasis and AD Treatmenthttps://practicaldermatology.com/news/review-targeted-therapies-transform-psoriasis-and-ad-treatment/2488965/A new review published in Thérapie examines the evolving systemic treatment landscape for psoriasis and atopic dermatitis (AD), documented the expansion of targeted therapies for adults and children while identifying persistent gaps in comparative efficacy and long-term safety evidence.<
- Arcutis Announces Phase 3 Trial of ZORYVE Cream 0.3% for Moderate to Severe Atopic Dermatitishttps://practicaldermatology.com/news/arcutis-initiates-phase-3-trial-of-zoryve-cream-03-for-moderate-to-severe-atopic-dermatitis/2488934/Arcutis Biotherapeutics has enrolled the first participant in INTEGUMENT-3, a Phase 3 clinical trial evaluating ZORYVE (roflumilast) cream 0.3% for moderate to severe atopic dermatitis in children and adults aged 6 years and older. The randomized, double-blind, vehic
- Early Emollient Therapy Linked to Lower Atopic Dermatitis Prevalence at Age 5https://practicaldermatology.com/news/early-emollient-therapy-linked-to-lower-atopic-dermatitis-prevalence-at-age-5/2488916/Early, short-term emollient therapy initiated shortly after birth was associated with lower atopic dermatitis (AD) prevalence and severity at age 5 years among high-risk children, according to long-term findings from the STOP-AD randomized controlled trial published in Pediatric Allergy and Immun
- FDA Approves Tildrakizumab for Adults With Active Psoriatic Arthritishttps://practicaldermatology.com/news/fda-approves-tildrakizumab-for-adults-with-active-psoriatic-arthritis/2488879/The US Food and Drug Administration (FDA) has approved tildrakizumab-asmn (ILUMYA; Sun Pharmaceutical Industries) for the treatment of adults with active psoriatic arthritis (PsA), according to an announcement from the company. The approval expands the use of the IL-23 inhibitor, which was
- Analysis: Estrogen Therapy Linked to Twofold Higher Odds of Porphyria Cutanea Tardahttps://practicaldermatology.com/news/analysis-estrogen-therapy-linked-to-twofold-higher-odds-of-porphyria-cutanea-tarda/2488877/New research published in JAMA Dermatology finds an association between estrogen-containing therapies and porphyria cutanea tarda, with differences observed by administration route. Researchers on the study examined whether estrogen exposure was associated with new PCT diagnoses a
- Analysis: Fewer Than Half of Patients With Multisite Mucous Membrane Pemphigoid Achieve Complete Remissionhttps://practicaldermatology.com/news/fewer-than-half-of-patients-with-multisite-mucous-membrane-pemphigoid-achieve-complete-remission/2488854/A retrospective study published in JAMA Dermatology indicated fewer than half of patients with multisite mucous membrane pemphigoid (MMP) achieved simultaneous complete remission across all affected sites, despite widespread improvement with treatment. Researchers at the
- Analysis Identifies Distinct Keratinocyte and Fibroblast Niches in Severe HShttps://practicaldermatology.com/news/study-examines-pathogenic-keratinocyte-states-and-fibroblast-niches-in-severe-hs/2488815/Researchers identified a pathogenic keratinocyte state and spatially distinct fibroblast populations in severe hidradenitis suppurativa (HS), providing new insights into epithelial–stromal and immune cell interactions that may contribute to disease persistence. The study authors, publishin
- Study: Bimekizumab Achieves Complete Psoriasis Clearance in Most Patients at 2 Yearshttps://practicaldermatology.com/news/bimekizumab-achieves-complete-psoriasis-clearance-in-most-of-patients-at-2-years-study/2488814/A 2-year multicenter real-world study published in the Journal of the American Academy of Dermatology (JAAD) found that 71.1% of adults with plaque psoriasis treated with bimekizumab achieved complete skin clearance, with treatment persistence approaching 89% at week 104. The retrospective